[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR199802240T2 - - Google Patents

Info

Publication number
TR199802240T2
TR199802240T2 TR1998/02240T TR9802240T TR199802240T2 TR 199802240 T2 TR199802240 T2 TR 199802240T2 TR 1998/02240 T TR1998/02240 T TR 1998/02240T TR 9802240 T TR9802240 T TR 9802240T TR 199802240 T2 TR199802240 T2 TR 199802240T2
Authority
TR
Turkey
Application number
TR1998/02240T
Other languages
English (en)
Inventor
Rorbert Busch Frank
Anne Rose Carol
James Shine Russell
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of TR199802240T2 publication Critical patent/TR199802240T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)

Abstract

Bu bulus
TR1998/02240T 1996-05-07 1997-04-10 TR199802240T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
TR199802240T2 true TR199802240T2 (tr) 1999-02-22

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02240T TR199802240T2 (tr) 1996-05-07 1997-04-10

Country Status (41)

Country Link
US (1) US6245765B1 (tr)
EP (1) EP0918772B1 (tr)
JP (1) JP3494659B2 (tr)
KR (1) KR100333215B1 (tr)
CN (1) CN1091769C (tr)
AP (1) AP765A (tr)
AR (1) AR007004A1 (tr)
AT (1) ATE278689T1 (tr)
AU (1) AU731267B2 (tr)
BG (1) BG63544B1 (tr)
BR (1) BR9709889A (tr)
CA (1) CA2252898C (tr)
CO (1) CO4940466A1 (tr)
CZ (1) CZ289215B6 (tr)
DE (1) DE69731094T2 (tr)
DK (1) DK0918772T3 (tr)
DZ (1) DZ2222A1 (tr)
EA (1) EA001190B1 (tr)
EG (1) EG24076A (tr)
ES (1) ES2229342T3 (tr)
GT (1) GT199700052A (tr)
HK (1) HK1017892A1 (tr)
HR (1) HRP970236B1 (tr)
ID (1) ID16867A (tr)
IL (1) IL126591A (tr)
IS (1) IS2080B (tr)
MA (1) MA24171A1 (tr)
MY (1) MY119997A (tr)
NO (1) NO312514B1 (tr)
NZ (1) NZ332218A (tr)
OA (1) OA10909A (tr)
PL (1) PL188330B1 (tr)
PT (1) PT918772E (tr)
SI (1) SI0918772T1 (tr)
SK (1) SK282837B6 (tr)
TN (1) TNSN97074A1 (tr)
TR (1) TR199802240T2 (tr)
TW (1) TW491847B (tr)
UA (1) UA46840C2 (tr)
WO (1) WO1997042191A1 (tr)
ZA (1) ZA973876B (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
CA2410618A1 (en) * 2000-06-02 2001-12-06 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2004100992A2 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
WO2005016325A2 (en) 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
CA2591670A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
EP2146577A1 (en) * 2007-05-18 2010-01-27 Scidose, Llc Ziprasidone formulations
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
CN107625728A (zh) * 2010-10-18 2018-01-26 大日本住友制药株式会社 注射用缓释制剂
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
AU730856C (en) 1996-05-07 2001-11-15 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist

Also Published As

Publication number Publication date
SK282837B6 (sk) 2002-12-03
SI0918772T1 (en) 2005-02-28
TW491847B (en) 2002-06-21
AP765A (en) 1999-09-17
CN1216991A (zh) 1999-05-19
BR9709889A (pt) 1999-08-10
AR007004A1 (es) 1999-10-13
EG24076A (en) 2008-05-11
HRP970236A2 (en) 1998-06-30
BG63544B1 (bg) 2002-04-30
HRP970236B1 (en) 2002-12-31
DK0918772T3 (da) 2005-01-10
EA001190B1 (ru) 2000-12-25
CA2252898A1 (en) 1997-11-13
ES2229342T3 (es) 2005-04-16
MY119997A (en) 2005-08-30
AU731267B2 (en) 2001-03-29
OA10909A (en) 2001-10-26
EA199800912A1 (ru) 1999-04-29
CA2252898C (en) 2003-04-08
WO1997042191A1 (en) 1997-11-13
PL329884A1 (en) 1999-04-12
PL188330B1 (pl) 2005-01-31
EP0918772A1 (en) 1999-06-02
NO312514B1 (no) 2002-05-21
SK150898A3 (en) 2000-02-14
KR20000010824A (ko) 2000-02-25
NO985194D0 (no) 1998-11-06
NZ332218A (en) 2005-02-25
CO4940466A1 (es) 2000-07-24
AU2174797A (en) 1997-11-26
IL126591A0 (en) 1999-08-17
ZA973876B (en) 1998-11-06
MA24171A1 (fr) 1997-12-31
KR100333215B1 (ko) 2002-06-20
IS2080B (is) 2006-02-15
EP0918772B1 (en) 2004-10-06
JPH11509867A (ja) 1999-08-31
UA46840C2 (uk) 2002-06-17
IS4874A (is) 1998-10-20
HK1017892A1 (en) 1999-12-03
TNSN97074A1 (fr) 2005-03-15
CN1091769C (zh) 2002-10-02
BG102892A (en) 1999-09-30
CZ349398A3 (cs) 1999-09-15
CZ289215B6 (cs) 2001-12-12
AP9700976A0 (en) 1997-07-31
DE69731094D1 (de) 2004-11-11
IL126591A (en) 2001-11-25
JP3494659B2 (ja) 2004-02-09
NO985194L (no) 1998-11-06
ID16867A (id) 1997-11-20
DZ2222A1 (fr) 2002-12-03
US6245765B1 (en) 2001-06-12
PT918772E (pt) 2004-12-31
DE69731094T2 (de) 2006-02-23
ATE278689T1 (de) 2004-10-15
GT199700052A (es) 2001-08-29

Similar Documents

Publication Publication Date Title
TR199802240T2 (tr)
ES2180899T3 (es) Dihidrato d de olanzapina.
DK1489082T3 (da) Mellemprodukter
ES2110386T3 (es) Conjugados de interferon.
BR9704713A (pt) Combinação estabilizadora
TR199701074T1 (tr) Sinerjistik bilesimler.
DE69622751D1 (de) Arbeitsplatz
DE59704994D1 (de) Kombinationsinstrument
DE69732364D1 (de) Ionenquelle
DE69713376D1 (de) Elektrolumineszierende hintergrundbeleuchtete anordnungen
DE69738387D1 (de) Lautsprecher
DK0866843T3 (da) Desodoriseringsanlæg
BR9707514A (pt) Inibidor de neovascularizacão
DE69731329D1 (de) Lautsprecher
BR9703909A (pt) Formador de blocos
DE59710374D1 (de) Kombinationswaage
DE59709096D1 (de) Kombinationswaage
DE69727735D1 (de) Lautsprecher
DE69617417D1 (de) Einfach-Potential Ionenquelle
DE59703860D1 (de) Substituierte 2-phenylpyridine
DE69732264D1 (de) Freisprecheinrichtung
KR980006003U (ko) 스피커
KR970003345U (ko) 콘센트
NO984585D0 (no) Akustisk kilde II
IDS000000155A (id) Suatu penyempurnaan bagian pengembang payung